Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month Low After Insider Selling

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s share price hit a new 52-week low during mid-day trading on Wednesday following insider selling activity. The company traded as low as $17.82 and last traded at $18.94, with a volume of 157800 shares. The stock had previously closed at $18.65.

Specifically, CFO Benjamin Hohl sold 3,250 shares of the business’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $18.69, for a total transaction of $60,742.50. Following the completion of the transaction, the chief financial officer now owns 23,000 shares of the company’s stock, valued at approximately $429,870. The trade was a 12.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Analysts Set New Price Targets

Separately, HC Wainwright lifted their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 21st.

Enliven Therapeutics Trading Up 4.8 %

The stock has a market capitalization of $972.73 million, a P/E ratio of -10.45 and a beta of 1.03. The business’s fifty day simple moving average is $19.16 and its two-hundred day simple moving average is $22.47.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. On average, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Trading of Enliven Therapeutics

A number of hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after purchasing an additional 1,114 shares in the last quarter. GAMMA Investing LLC increased its holdings in Enliven Therapeutics by 3,058.1% in the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock valued at $53,000 after buying an additional 2,630 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Enliven Therapeutics in the 4th quarter valued at $97,000. BNP Paribas Financial Markets acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at $112,000. Finally, ExodusPoint Capital Management LP bought a new position in shares of Enliven Therapeutics during the 4th quarter worth about $200,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.